
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3422161/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181.	1.8	4
2	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology, 2022, 19, 305-320.	3.8	9
3	TRAP1 Chaperones the Metabolic Switch in Cancer. Biomolecules, 2022, 12, 786.	4.0	14
4	Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer. Biomolecules, 2022, 12, 928.	4.0	2
5	A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand. Cell Reports, 2022, 40, 111039.	6.4	15
6	The Role of Heat Shock Protein-90 in the Pathogenesis of Birt-Hogg-Dubé and Tuberous Sclerosis Complex Syndromes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 322-326.	1.6	6
7	MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 316-321.	1.6	9
8	First Virtual International Congress on Cellular and Organismal Stress Responses, November 5–6, 2020. Cell Stress and Chaperones, 2021, 26, 289-295.	2.9	0
9	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e1-367.e5.	1.6	11
10	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	3.7	9
11	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. Nature Structural and Molecular Biology, 2021, 28, 662-670.	8.2	19
12	Hsp90 chaperone code and the tumor suppressor VHL cooperatively regulate the mitotic checkpoint. Cell Stress and Chaperones, 2021, 26, 965-971.	2.9	9
13	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15.	1.6	7
14	Decrypting the chaperone code. Journal of Biological Chemistry, 2021, 296, 100293.	3.4	12
15	Fumarate hydratase as a therapeutic target in renal cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 923-936.	3.4	12
16	Post-translational modifications of Hsp90 and translating the chaperone code. Journal of Biological Chemistry, 2020, 295, 11099-11117.	3.4	115
17	Structure and function of the co-chaperone protein phosphatase 5 in cancer. Cell Stress and Chaperones, 2020, 25, 383-394.	2.9	28
18	Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90–Client Interactions. Chemistry - A European Journal, 2020, 26, 9459-9465.	3.3	39

#	Article	IF	CITATIONS
19	Structural and functional regulation of lactate dehydrogenase-A in cancer. Future Medicinal Chemistry, 2020, 12, 439-455.	2.3	33
20	Design of Disruptors of the Hsp90–Cdc37 Interface. Molecules, 2020, 25, 360.	3.8	14
21	Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study Journal of Clinical Oncology, 2020, 38, 5066-5066.	1.6	0
22	Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis. Cell Reports, 2019, 28, 1894-1906.e6.	6.4	50
23	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Reports, 2019, 26, 1344-1356.e5.	6.4	38
24	Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 182.e9-182.e15.	1.6	10
25	The multiple facets of the Hsp90 machine. Nature Structural and Molecular Biology, 2019, 26, 92-95.	8.2	9
26	Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity. Oncotarget, 2019, 10, 5824-5834.	1.8	18
27	Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity. IScience, 2018, 1, 87-96.	4.1	29
28	Detecting Posttranslational Modifications of Hsp90. Methods in Molecular Biology, 2018, 1709, 209-219.	0.9	13
29	Detection and Analysis of Extracellular Hsp90 (eHsp90). Methods in Molecular Biology, 2018, 1709, 321-329.	0.9	9
30	The mTOR Independent Function of Tsc1 and FNIPs. Trends in Biochemical Sciences, 2018, 43, 935-937.	7.5	14
31	<i>PBRM1</i> mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment Journal of Clinical Oncology, 2018, 36, 12091-12091.	1.6	4
32	Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis. Oncotarget, 2018, 9, 22220-22229.	1.8	11
33	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study Journal of Clinical Oncology, 2018, 36, 640-640.	1.6	0
34	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study Journal of Clinical Oncology, 2018, 36, e16586-e16586.	1.6	0
35	Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer. Cell Reports, 2017, 21, 1883-1895.	6.4	40
36	Tumor suppressor Tsc1 is a new Hsp90 coâ€chaperone that facilitates folding of kinase and nonâ€kinase clients. EMBO Journal, 2017, 36, 3650-3665.	7.8	64

#	Article	IF	CITATIONS
37	Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors. Advances in Cancer Research, 2016, 129, 31-50.	5.0	36
38	Structural and functional basis of protein phosphatase 5 substrate specificity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9009-9014.	7.1	66
39	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nature Communications, 2016, 7, 12037.	12.8	56
40	Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. Journal of Urology, 2016, 195, 847-851.	0.4	14
41	Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. Cell Reports, 2016, 14, 872-884.	6.4	60
42	Targeting Hsp90 in Non-Cancerous Maladies. Current Topics in Medicinal Chemistry, 2016, 16, 2792-2804.	2.1	12
43	The dynamic interactome of human Aha1 upon Y223 phosphorylation. Data in Brief, 2015, 5, 752-755.	1.0	10
44	c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Reports, 2015, 12, 1006-1018.	6.4	54
45	Targeting Hsp90 in urothelial carcinoma. Oncotarget, 2015, 6, 8454-8473.	1.8	31
46	Asymmetric Hsp90ÂN Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors. Molecular Cell, 2014, 53, 317-329.	9.7	101
47	The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models. Cancer Research, 2013, 73, 7022-7033.	0.9	49
48	Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Medicinal Chemistry, 2013, 5, 1059-1071.	2.3	54
49	Post-translational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget, 2013, 4, 1065-1074.	1.8	58
50	Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle, 2012, 11, 3649-3655.	2.6	23
51	Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2937-2942.	7.1	107
52	Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy. Current Molecular Medicine, 2012, 12, 1125-1141.	1.3	47
53	Dynamic Tyrosine Phosphorylation Modulates Cycling of the HSP90-P50CDC37-AHA1 Chaperone Machine. Molecular Cell, 2012, 47, 434-443.	9.7	113
54	Activity of the yeast zincâ€finger transcription factor War1 is lost with alanine mutation of two putative phosphorylation sites in the activation domain. Yeast, 2012, 29, 39-44.	1.7	9

#	Article	IF	CITATIONS
55	Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 648-655.	4.1	248
56	Threonine 22 Phosphorylation Attenuates Hsp90 Interaction with Cochaperones and Affects Its Chaperone Activity. Molecular Cell, 2011, 41, 672-681.	9.7	146
57	A systematic protocol for the characterization of Hsp90 modulators. Bioorganic and Medicinal Chemistry, 2011, 19, 684-692.	3.0	80
58	Detecting HSP90 Phosphorylation. Methods in Molecular Biology, 2011, 787, 67-74.	0.9	7
59	Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget, 2011, 2, 407-417.	1.8	53
60	Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer, 2010, 10, 537-549.	28.4	1,306
61	Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle, 2010, 9, 2310-2316.	2.6	74
62	Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function. Molecular Cell, 2010, 37, 333-343.	9.7	165
63	Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 11± Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. Molecular and Cellular Biology, 2009, 29, 4080-4090.	2.3	212
64	The complex dance of the molecular chaperone Hsp90. Trends in Biochemical Sciences, 2009, 34, 223-226.	7.5	40
65	The Hsp90/Cdc37p chaperone system is a determinant of molybdate resistance in <i>Saccharomyces cerevisiae</i> . Yeast, 2009, 26, 339-347.	1.7	9
66	Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nature Structural and Molecular Biology, 2009, 16, 1141-1147.	8.2	78
67	Visualizing the twists and turns of a molecular chaperone. Nature Structural and Molecular Biology, 2009, 16, 235-236.	8.2	13
68	Novel stress responses facilitate <i>Saccharomyces cerevisiae</i> growth in the presence of the monocarboxylate preservatives. Yeast, 2008, 25, 169-177.	1.7	60
69	Hsp90-Dependent Activation of Protein Kinases Is Regulated by Chaperone-Targeted Dephosphorylation of Cdc37. Molecular Cell, 2008, 31, 886-895.	9.7	184
70	Hog1 Mitogen-Activated Protein Kinase Phosphorylation Targets the Yeast Fps1 Aquaglyceroporin for Endocytosis, Thereby Rendering Cells Resistant to Acetic Acid. Molecular and Cellular Biology, 2007, 27, 6446-6456.	2.3	225
71	In the Yeast Heat Shock Response, Hsf1-Directed Induction of Hsp90 Facilitates the Activation of the Slt2 (Mpk1) Mitogen-Activated Protein Kinase Required for Cell Integrity. Eukaryotic Cell, 2007, 6, 744-752.	3.4	49
72	Expressed as the sole Hsp90 of yeast, the α and β isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor radicicol. FEBS Journal, 2007, 274, 4453-4463.	4.7	76

#	Article	IF	CITATIONS
73	Hog1p mitogen-activated protein kinase determines acetic acid resistance inSaccharomyces cerevisiae. FEMS Yeast Research, 2006, 6, 1274-1280.	2.3	84
74	Expressed in the Yeast Saccharomyces cerevisiae , Human ERK5 Is a Client of the Hsp90 Chaperone That Complements Loss of the Slt2p (Mpk1p) Cell Integrity Stress-Activated Protein Kinase. Eukaryotic Cell, 2006, 5, 1914-1924.	3.4	60
75	Qri2/Nse4, a component of the essential Smc5/6 DNA repair complex. Molecular Microbiology, 2005, 55, 1735-1750.	2.5	43
76	Overexpressed Sod1p acts either to reduce or to increase the lifespans and stress resistance of yeast, depending on whether it is Cu2+-deficient or an active Cu,Zn-superoxide dismutase. Aging Cell, 2005, 4, 41-52.	6.7	43
77	Screening the yeast deletant mutant collection for hypersensitivity and hyper-resistance to sorbate, a weak organic acid food preservative. Yeast, 2004, 21, 927-946.	1.7	73
78	Mnsod overexpression extends the yeast chronological (G0) life span but acts independently of Sir2p histone deacetylase to shorten the replicative life span of dividing cells. Free Radical Biology and Medicine, 2003, 34, 1599-1606.	2.9	89
79	Weak organic acid stress inhibits aromatic amino acid uptake by yeast, causing a strong influence of amino acid auxotrophies on the phenotypes of membrane transporter mutants. FEBS Journal, 2003, 270, 3189-3195.	0.2	110
80	Sensitivity to Hsp90-targeting drugs can arise with mutation to the Hsp90 chaperone, cochaperones and plasma membrane ATP binding cassette transporters of yeast. FEBS Journal, 2003, 270, 4689-4695.	0.2	52
81	Moderately lipophilic carboxylate compounds are the selective inducers of theSaccharomyces cerevisiaePdr12p ATP-binding cassette transporter. Yeast, 2003, 20, 575-585.	1.7	63
82	Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90β, a property that can be exploited in screens for new Hsp90 chaperone inhibitors. Gene, 2003, 302, 165-170.	2.2	51
83	War1p, a Novel Transcription Factor Controlling Weak Acid Stress Response in Yeast. Molecular and Cellular Biology, 2003, 23, 1775-1785.	2.3	129
84	Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1. Molecular Cell, 2002, 10, 1307-1318.	9.7	487
85	The shortened replicative life span of prohibitin mutants of yeast appears to be due to defective mitochondrial segregation in old mother cells. Aging Cell, 2002, 1, 149-157.	6.7	69
86	The ZbYME2 gene from the food spoilage yeast Zygosaccharomyces bailii confers not only YME2 functions in Saccharomyces cerevisiae, but also the capacity for catabolism of sorbate and benzoate, two major weak organic acid preservatives. Molecular Microbiology, 2001, 42, 919-930.	2.5	54
87	Targeted gene deletion inZygosaccharomyces bailii. Yeast, 2001, 18, 173-186.	1.7	47